Checchi Capital Advisers LLC Has $266,000 Stock Position in CVS Health Co. (NYSE:CVS)

Checchi Capital Advisers LLC cut its stake in CVS Health Co. (NYSE:CVS) by 28.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,921 shares of the pharmacy operator’s stock after selling 2,365 shares during the period. Checchi Capital Advisers LLC’s holdings in CVS Health were worth $266,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of CVS. AMF Tjanstepension AB increased its stake in shares of CVS Health by 124.1% in the 3rd quarter. AMF Tjanstepension AB now owns 61,744 shares of the pharmacy operator’s stock valued at $3,882,000 after buying an additional 34,198 shares during the period. Pallas Capital Advisors LLC boosted its holdings in CVS Health by 82.6% in the third quarter. Pallas Capital Advisors LLC now owns 13,616 shares of the pharmacy operator’s stock valued at $856,000 after acquiring an additional 6,158 shares during the last quarter. Pinnacle Associates Ltd. increased its position in CVS Health by 3.8% in the third quarter. Pinnacle Associates Ltd. now owns 174,752 shares of the pharmacy operator’s stock worth $10,988,000 after purchasing an additional 6,400 shares during the period. Fiducient Advisors LLC acquired a new position in CVS Health during the 3rd quarter valued at about $261,000. Finally, Catalyst Financial Partners LLC boosted its stake in shares of CVS Health by 8.5% in the 3rd quarter. Catalyst Financial Partners LLC now owns 4,402 shares of the pharmacy operator’s stock valued at $277,000 after purchasing an additional 345 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other CVS Health news, Director Michael F. Mahoney bought 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was acquired at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the transaction, the director now owns 39,356 shares in the company, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.24% of the stock is owned by corporate insiders.

CVS Health Trading Up 1.1 %

Shares of NYSE:CVS opened at $64.54 on Friday. The firm has a market cap of $81.37 billion, a price-to-earnings ratio of 17.63, a PEG ratio of 0.98 and a beta of 0.61. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $80.75. The company’s fifty day simple moving average is $53.90 and its 200 day simple moving average is $56.40.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, research analysts forecast that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd were paid a dividend of $0.665 per share. The ex-dividend date was Thursday, January 23rd. This represents a $2.66 annualized dividend and a dividend yield of 4.12%. CVS Health’s dividend payout ratio is currently 72.68%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CVS shares. Barclays boosted their price target on shares of CVS Health from $71.00 to $73.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Evercore ISI upped their target price on shares of CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Monday, January 27th. Truist Financial raised their price target on CVS Health from $60.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft upgraded CVS Health from a “hold” rating to a “buy” rating and set a $66.00 price objective for the company in a report on Tuesday, December 3rd. Finally, Wells Fargo & Company boosted their target price on CVS Health from $68.00 to $73.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, CVS Health has an average rating of “Moderate Buy” and a consensus price target of $70.00.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.